Open access
Sep 2026
Targeting the DNHD1‑HDAC6 axis inactivates prostate cancer cell aggressiveness in vitro, suggesting potential therapeutic vulnerability.
Prostate cancer progression toward an aggressive, therapy‑resistant disease state remains a major clinical challenge, indicating a need to identify novel molecular drivers of such progression and actionable therapeutic targets. The present study analyzed the role of dynein heavy chain domain 1 (DNHD1), a previously unc...
An-Nie-On-Nei Lee, Chia-Chang Wu, Su-Wei Hu et al.
· Oncology Report · 0 citations